Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of 7-Ethyl-10-Hydroxycamptothecin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 18/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CASP1 | P29466 | 1/20 | 0.67 |
| ▸ | CASP7 | P55210 | 1/20 | 0.67 |
| ▸ | HBB | P68871 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL34018 | 0.95 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2ALDH1A1 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL733477 | 0.95 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2ALDH1A1 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL16072280 | 0.95 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2ALDH1A1 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL13420265 | 0.95 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2ALDH1A1 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL29787648 | 0.95 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2ALDH1A1 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL29359781 | 0.95 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2ALDH1A1 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL29354078 | 0.95 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2ALDH1A1 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL28292269 | 0.94 | MEN1 (0.98) | MEN1KMT2ATOP1SMN1; SMN2ALDH1A1 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL27680702 | 0.94 | MEN1 (0.98) | MEN1KMT2ATOP1SMN1; SMN2ALDH1A1 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL1454961 | 0.94 | MEN1 (0.98) | MEN1KMT2ATOP1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118584020-A | Method for detecting 8 antitumor drugs and 3 active metabolites in blood | 济南和合医学检验有限公司 | 2024-09-03 | — | — | CN | claimed |
| CN-117517500-A | Method for measuring irinotecan and metabolites thereof in serum by high performance liquid chromatography-tandem mass spectrometry | 苏州大学附属儿童医院 | 2024-02-06 | — | — | CN | claimed |
| US-20260069707-A1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES | HALOZYME, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| CN-118584020-A | Method for detecting 8 antitumor drugs and 3 active metabolites in blood | 济南和合医学检验有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-117517500-A | Method for measuring irinotecan and metabolites thereof in serum by high performance liquid chromatography-tandem mass spectrometry | 苏州大学附属儿童医院 | 2024-02-06 | — | — | CN | disclosed |
| CN-117347525-A | Human serum irinotecan, SN-38G and APC metabolite detection method | 苏州大学附属儿童医院 | 2024-01-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069707-A1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES | CD22, CD2, CD44 | TOP1 1901/4885MEN1 800/4885KMT2A 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.